Status:
COMPLETED
A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40+ years
Brief Summary
Study to collect the data on Chronic Obstructive Pulmonary Disease (COPD) patients who were administered with Long-Acting Beta-Agonist/ Long-Acting Muscarinic Antagonist (LABA/LAMA) (Fixed-dose Combin...
Eligibility Criteria
Inclusion
- Patients who fulfil ALL the following criteria are included.
- Patients who diagnosed with COPD who were prescribed with LABA/LABA (FDC or free combo) as a new initiation or switching from other therapy (i.e., single/dual/triple), or newly receiving LAMA treatment for 3 months at least prior to 30 June 2018
- Male or female patients ≥ 40 years of age
Exclusion
- 1\. Patients who meet the following criterion are not included.
- Patients with documented diagnosis of bronchial asthma, asthma-COPD overlap syndrome (ACOS), bronchiectasis, cystic fibrosis, or lung cancer
Key Trial Info
Start Date :
December 29 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2020
Estimated Enrollment :
1617 Patients enrolled
Trial Details
Trial ID
NCT04011475
Start Date
December 29 2019
End Date
October 31 2020
Last Update
June 14 2022
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Ditmanson Medical Foundation Chia - Yi Christian Hospital
Chia YI City, Taiwan, 600
2
CGMH Chia YI
Chia YI City, Taiwan, 613
3
Eda hospital
Kaohsiung City, Taiwan, 824
4
CGMH Kaohsiung
Kaohsiung City, Taiwan, 833